Clincosm LogoSign in Get a demo

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

Sponsor
Tanta University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04345406
Collaborator
(none)
60
Enrollment
1
Location
2
Arms
115.5
Anticipated Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

ACEIs as treatment for COVID19

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

ACEIs as suggested treatment for COVID19

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomized Trial of ACEIs in Treatment of COVID-19
Anticipated Study Start Date :
Apr 15, 2020
Anticipated Primary Completion Date :
Dec 1, 2029
Anticipated Study Completion Date :
Dec 1, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: ACEIs

ACEIs with conventional treatment for COVID19

Drug: ACEIs
Captopril or enalapril
Other Names:
  • Enalapril, Captopril

    • Drug: Conventional treatment
    alexoquine
    Other Names:
  • chloroquine

    		•
    Experimental: Conventional treatment of COVID19

    Conventional treatment of COVID19

    Drug: Conventional treatment
    alexoquine
    Other Names:
  • chloroquine

    		•

    Outcome Measures

    Primary Outcome Measures

    1. number of patients with virological cure [6 months]

      number of patients with virological cure

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients infected with covid 19
    Exclusion Criteria:
    • allergy or contraindications to the drug

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tanta University Tanta Egypt 35111

    Sponsors and Collaborators

    • Tanta University

    Investigators

    • Principal Investigator: Sherief Abd-Elsalam, ass. prof., Tanta University Faculty of medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sherief Abd-Elsalam, assistant professor of tropical medicine and infectious diseases, Tanta University
    ClinicalTrials.gov Identifier:
    NCT04345406
    Other Study ID Numbers:
    • ACEIS COVID 19
    First Posted:
    Apr 14, 2020
    Last Update Posted:
    Apr 14, 2020
    Last Verified:
    Apr 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Chloroquine
    Enalapril
    Captopril

    Study Results

    No Results Posted as of Apr 14, 2020